⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ARWR News
Arrowhead Research Corporation
Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences
businesswire.com
ARWR
Familial Hypercholesterolemia Market Intelligence Report 2025-2035 Featuring Regeneron, Amgen, Esperion, Aegerion, Novartis and Other Key Players - Precision Medicine Fuels Personalized Treatment Approaches
globenewswire.com
REGN
AMGN
ESPR
ARWR
Familial Chylomicronemia Syndrome Global Market Analysis and Forecast, 2025-2035: Healthcare Access and Education Enhance FCS Market Expansion
globenewswire.com
IONS
ARWR
ABT
Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results
businesswire.com
ARWR
Chronic Heart Failure Clinical Trial Pipeline Shows Potential with Active Contributions from 25+ Key Companies | DelveInsight
globenewswire.com
CYTK
BAYRY
LLY
BCDA
MESO
TNSA
NVO
AZN
BMY
ITCI
JNJ
AMGN
ARWR
Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1
businesswire.com
SRPT
ARWR
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
businesswire.com
ARWR
SRPT
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO ® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
businesswire.com
ARWR
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results
businesswire.com
ARWR
Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences
businesswire.com
ARWR